Government-Owned Inventions; Availability for Licensing, 55904-55905 [2018-24468]

Download as PDF daltland on DSKBBV9HB2PROD with NOTICES 55904 Federal Register / Vol. 83, No. 217 / Thursday, November 8, 2018 / Notices least five business days in advance of the event. Written Public Comments: NTP invites written public comments. Guidelines for public comments are available at https://ntp.niehs.nih.gov/ ntp/about_ntp/guidelines_public_ comments_508.pdf. The deadline for submission of written comments is December 3, 2018. Written public comments should be submitted through the meeting website. Persons submitting written comments should include name, affiliation, mailing address, phone, email, and sponsoring organization (if any). Written comments received in response to this notice will be posted on the NTP website, and the submitter will be identified by name, affiliation, and sponsoring organization (if any). Oral Public Comment Registration: The agenda allows for two public comment periods: The first comment period on the CLARITY–BPA Research Program: Integration Report Strategy (5 commenters, up to 5 minutes per speaker) and the second comment period on the peer review of the Draft Report on Carcinogens Monograph on Night Shift Work and Light at Night (5 commenters, up to 5 minutes per speaker); oral comments may be presented in person at NIEHS or by teleconference line. Registration for oral comments is on or before December 3, 2018, at https://ntp.niehs.nih.gov/go/165. Registration is on a first-come, firstserved basis, and registrants will be assigned a number in their confirmation email. Each organization is allowed one time slot per comment period. After the maximum number of speakers per comment period is exceeded, individuals registered to provide oral comment will be placed on a wait list and notified should an opening become available. Commenters will be notified after December 3, 2018, about the actual time allotted per speaker, and the teleconference number will be sent to those registered to give oral comments by teleconference line. If possible, oral public commenters should send a copy of their slides and/ or statement or talking points to NTPMeetings@icf.com by December 3, 2018. Meeting Materials: The preliminary meeting agenda is available on the meeting web page (https:// ntp.niehs.nih.gov/go/165) and will be updated one week before the meeting. Individuals are encouraged to access the meeting web page to stay abreast of the most current information regarding the meeting. Background Information on the BSC: The BSC is a technical advisory body comprised of scientists from the public VerDate Sep<11>2014 16:51 Nov 07, 2018 Jkt 247001 and private sectors that provides primary scientific oversight to the NTP. Specifically, the BSC advises the NTP on matters of scientific program content, both present and future, and conducts periodic review of the program for the purpose of determining and advising on the scientific merit of its activities and their overall scientific quality. Its members are selected from recognized authorities knowledgeable in fields such as toxicology, pharmacology, pathology, biochemistry, epidemiology, risk assessment, carcinogenesis, mutagenesis, molecular biology, behavioral toxicology, neurotoxicology, immunotoxicology, reproductive toxicology or teratology, and biostatistics. Members serve overlapping terms of up to four years. The BSC usually meets biannually. The authority for the BSC is provided by 42 U.S.C. 217a, section 222 of the Public Health Service Act (PHS), as amended. The BSC is governed by the provisions of the Federal Advisory Committee Act, as amended (5 U.S.C. app.), which sets forth standards for the formation and use of advisory committees. Dated: October 31, 2018. Brian R. Berridge, Associate Director, National Toxicology Program. [FR Doc. 2018–24472 Filed 11–7–18; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Government-Owned Inventions; Availability for Licensing AGENCY: National Institutes of Health, HHS. ACTION: Notice. The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing. FOR FURTHER INFORMATION CONTACT: Dr. Jenish Patel, Ph.D., 240–669–2894; jenish.patel@nih.gov. Licensing information and copies of the U.S. patent application listed below may be obtained by communicating with the indicated licensing contact at the Technology Transfer and Intellectual SUMMARY: PO 00000 Frm 00054 Fmt 4703 Sfmt 4703 Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD, 20852; tel. 301–496–2644. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished patent applications. SUPPLEMENTARY INFORMATION: Technology description follows. Universal Influenza Virus Probes for Enrichment of Influenza Viral Sequences Description of Technology: This technology is a set of influenza virus enrichment probes developed to increase the sensitivity of sequencebased, universal detection of all influenza viruses. This universal influenza enrichment probe set contains a unique set of 46,953 biotin-labeled, RNA probes, each 120 base-pairs long, that can be used to enrich for any influenza sequences without prior knowledge of type or subtype. This probe set can capture and enrich influenza viral sequences selectively and effectively in a variety of samples, such as clinical samples with degraded nucleotides or samples containing very low amounts of influenza virus, thus making it a valuable tool for influenza virus diagnoses and surveillance. This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as well as for further development and evaluation under a research collaboration. Potential Commercial Applications: • Influenza diagnostics; influenza surveillance Competitive Advantages: • Highly sensitive detection of influenza viruses • Detection of any influenza viruses in a variety of samples Development Stage: • In vitro Testing Inventors: Yongli Xiao, Ph.D., (NIAID), Jeffrey Taubenberger, Ph.D., (NIAID), and Zong-Mei Sheng, Ph.D. (NIAID) Publications: Xiao Y, et al. Design and validation of a universal influenza virus enrichment probe set and its utility in deep sequence analysis of primary cloacal swab surveillance samples of wild birds. Virology, 2018, Nov; 524:182–191 [PMID 30212665] Intellectual Property: HHS Reference No. E–032–2018/0—US–01 Patent Application No. 62/611,734 filed December 29, 2017. Licensing Contact: Jenish Patel, Ph.D., 240–669–2894; jenish.patel@nih.gov Collaborative Research Opportunity: The National Institute of Allergy and Infectious Diseases (NIAID) is also E:\FR\FM\08NON1.SGM 08NON1 55905 Federal Register / Vol. 83, No. 217 / Thursday, November 8, 2018 / Notices seeking statements of capability or interest from parties interested in collaborative research, such as from bioanalytic research groups to develop rapid influenza monitoring, diagnostic, and surveillance devices and biotechnology companies to formulate and test influenza next generation sequencing kits for challenging influenza infected samples, for example zoonotic infections of influenza A virus subtypes differing from currently circulating human influenza viruses or in mixed infections. NIAID will consider executing a Confidentiality Agreement with a prospective collaborator to facilitate receipt of a Capability Statement if requested. For collaboration opportunities, please contact Jenish Patel, Ph.D., 240–669– 2894; jenish.patel@nih.gov. Dated: October 19, 2018. Suzanne M. Frisbie, Deputy Director, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases. [FR Doc. 2018–24468 Filed 11–7–18; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Proposed Collection; 60-Day Comment Request; National Children’s Study (NCS) Vanguard Data and Sample Archive and Access System (Eunice Kennedy Shriver National Institute of Child Health and Human Development) AGENCY: National Institutes of Health, HHS. ACTION: Notice. In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on SUMMARY: electronic, mechanical, or other technological collection techniques or other forms of information technology. Proposed Collection Title: National Children’s Study (NCS) Vanguard Data and Sample Archive and Access System, 0925–0730 exp., date 2/28/ 2019—EXTENSION Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH). Need and Use of Information Collection: NICHD requires institutional and investigator contact information from users of the NCS Data and Sample Archive and Access System (NCS Archive). This information collected from potential data users is necessary to fulfill the requirements of their proposed research projects, ensure compliance with Department of Health and Human Services regulations for the protection of human subjects in research (45 CFR 46) and the Common Rule (45 CFR 46 Subpart A), and to document, track, and monitor the use of the NCS Archive, which provides opportunities for qualified researchers to use data and samples collected by the NCS Vanguard phase, for approved research projects. The information in addition will help NIH better understand the use of archived data and samples by the research community. There is no plan to publish the data collected under this request other than to post on the NCS Archive website the titles of approved research projects together with project investigators’ institutional affiliations. The data otherwise are for internal monitoring purposes only, to assess the archive resource requirements and for quality improvement. OMB approval is requested for 3 years. There are no costs to respondents other than their time. The total estimated annualized burden hours are 109. proposed data collection projects, the National Institutes of Health Eunice Kennedy Shriver National Institute of Child Health and Human Development will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval. DATES: Comments regarding this information collection are best assured of having their full effect if received within 60 days of the date of this publication. FOR FURTHER INFORMATION CONTACT: To obtain a copy of the data collection plans and instruments, submit comments in writing, or request more information on the proposed project, contact: Jack Moye, Jr., MD, Bldg. 6710B Rm. 2130 MSC 7002, 9000 Rockville Pike, Bethesda, MD, 20892–7002, or call non-toll-free number (301) 594–8624 or Email your request, including your address to: NCSArchive@s-3.net. Formal requests for additional plans and instruments must be requested in writing. SUPPLEMENTARY INFORMATION: Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995 requires: Written comments and/or suggestions from the public and affected agencies are invited to address one or more of the following points: (1) Whether the proposed collection of information is necessary for the proper performance of the function of the agency, including whether the information will have practical utility; (2) The accuracy of the agency’s estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) Ways to enhance the quality, utility, and clarity of the information to be collected; and (4) Ways to minimize the burden of the collection of information on those who are to respond, including the use of appropriate automated, ESTIMATED ANNUALIZED BURDEN HOURS Type of respondent daltland on DSKBBV9HB2PROD with NOTICES Research Research Research Research scientists scientists scientists scientists Number of respondents Form Average time per response (hours) Frequency of response Total annual burden hours ....... ....... ....... ....... NCS Vanguard Data User Agreement ................ NCS Vanguard Data Request Form ................... NCS Vanguard Data and Sample Request Form Research Materials Distribution Agreement ........ 300 50 50 100 1 1 1 1 10/60 20/60 30/60 10/60 50 17 25 17 Total ........................ .............................................................................. 500 500 ........................ 109 VerDate Sep<11>2014 16:51 Nov 07, 2018 Jkt 247001 PO 00000 Frm 00055 Fmt 4703 Sfmt 4703 E:\FR\FM\08NON1.SGM 08NON1

Agencies

[Federal Register Volume 83, Number 217 (Thursday, November 8, 2018)]
[Notices]
[Pages 55904-55905]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-24468]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The invention listed below is owned by an agency of the U.S. 
Government and is available for licensing to achieve expeditious 
commercialization of results of federally-funded research and 
development. Foreign patent applications are filed on selected 
inventions to extend market coverage for companies and may also be 
available for licensing.

FOR FURTHER INFORMATION CONTACT: Dr. Jenish Patel, Ph.D., 240-669-2894; 
[email protected]. Licensing information and copies of the U.S. 
patent application listed below may be obtained by communicating with 
the indicated licensing contact at the Technology Transfer and 
Intellectual Property Office, National Institute of Allergy and 
Infectious Diseases, 5601 Fishers Lane, Rockville, MD, 20852; tel. 301-
496-2644. A signed Confidential Disclosure Agreement will be required 
to receive copies of unpublished patent applications.

SUPPLEMENTARY INFORMATION: Technology description follows.

Universal Influenza Virus Probes for Enrichment of Influenza Viral 
Sequences

    Description of Technology:
    This technology is a set of influenza virus enrichment probes 
developed to increase the sensitivity of sequence-based, universal 
detection of all influenza viruses. This universal influenza enrichment 
probe set contains a unique set of 46,953 biotin-labeled, RNA probes, 
each 120 base-pairs long, that can be used to enrich for any influenza 
sequences without prior knowledge of type or subtype. This probe set 
can capture and enrich influenza viral sequences selectively and 
effectively in a variety of samples, such as clinical samples with 
degraded nucleotides or samples containing very low amounts of 
influenza virus, thus making it a valuable tool for influenza virus 
diagnoses and surveillance.
    This technology is available for licensing for commercial 
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as 
well as for further development and evaluation under a research 
collaboration.
    Potential Commercial Applications:
     Influenza diagnostics; influenza surveillance
    Competitive Advantages:
     Highly sensitive detection of influenza viruses
     Detection of any influenza viruses in a variety of samples
    Development Stage:
     In vitro Testing
    Inventors: Yongli Xiao, Ph.D., (NIAID), Jeffrey Taubenberger, 
Ph.D., (NIAID), and Zong-Mei Sheng, Ph.D. (NIAID)
    Publications: Xiao Y, et al. Design and validation of a universal 
influenza virus enrichment probe set and its utility in deep sequence 
analysis of primary cloacal swab surveillance samples of wild birds. 
Virology, 2018, Nov; 524:182-191 [PMID 30212665]
    Intellectual Property: HHS Reference No. E-032-2018/0--US-01 Patent 
Application No. 62/611,734 filed December 29, 2017.
    Licensing Contact: Jenish Patel, Ph.D., 240-669-2894; 
[email protected]
    Collaborative Research Opportunity: The National Institute of 
Allergy and Infectious Diseases (NIAID) is also

[[Page 55905]]

seeking statements of capability or interest from parties interested in 
collaborative research, such as from bio-analytic research groups to 
develop rapid influenza monitoring, diagnostic, and surveillance 
devices and biotechnology companies to formulate and test influenza 
next generation sequencing kits for challenging influenza infected 
samples, for example zoonotic infections of influenza A virus subtypes 
differing from currently circulating human influenza viruses or in 
mixed infections. NIAID will consider executing a Confidentiality 
Agreement with a prospective collaborator to facilitate receipt of a 
Capability Statement if requested. For collaboration opportunities, 
please contact Jenish Patel, Ph.D., 240-669-2894; [email protected].

    Dated: October 19, 2018.
Suzanne M. Frisbie,
Deputy Director, Technology Transfer and Intellectual Property Office, 
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2018-24468 Filed 11-7-18; 8:45 am]
 BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.